SuperworthModerna market cap MRNA
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $79.9B
- Highest close in our data
- $181.4B
- Sep 2021
Moderna is worth $79.9B at the close on Oct 23, 2026, at $200.10 a share.
That is up 668% over the last year and down 43% over five years.
Its highest close in our data was $181.4B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $79.9B | $12.1B | $89.8B | +555% |
| 2025 | $12.2B | $9.1B | $16.3B | −21% |
| 2024 | $15.4B | $14.2B | $63.9B | −59% |
| 2023 | $37.9B | $26.7B | $74.5B | −45% |
| 2022 | $69B | $46.3B | $86.7B | −33% |
| 2021 | $103B | $44.6B | $181.4B | +149% |
| 2020 | $41.3B | $6.1B | $62.1B | +536% |
| 2019 | $6.5B | $4.2B | $8.9B | n/a |
Against its peers
Companies in Biotechnology nearest Moderna's size, closest first, today.
| Company | Market cap |
|---|---|
| MRNAModerna | $79.9B |
| REGNRegeneron Pharmaceuticals | $82.9B |
| VRTXVertex Pharmaceuticals | $132.8B |
| ONCBeOne Medicines | $42.9B |
| ALNYAlnylam Pharmaceuticals | $30B |
| UTHRUnited Therapeutics | $25.2B |
| INCYIncyte | $23.5B |
| EXELExelixis | $16B |
| NBIXNeurocrine Biosciences | $14.5B |
| HALOHalozyme Therapeutics | $14.3B |
| TECHBIO-TECHNE | $11.4B |
| Peer median | $24.3B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Moderna
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.